William p. Arend

Q: What Schools Are Affiliated With William p. Arend

William p. Arend is affiliated with the following schools: University of Colorado Denver, University of Washington

William p. Arend's AcademicInfluence.com Rankings

William p. Arend

Philosophy

#6327

World Rank

#9348

Historical Rank

Logic

#3505

World Rank

#4680

Historical Rank

philosophy Degrees

Download Badge

Philosophy

William p. Arend's Degrees

Doctorate Medicine University of California, San Francisco

Why Is William p. Arend Influential?

(Suggest an Edit or Addition)

(See a Problem?)

William p. Arend's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. (2010) (2232)
The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). (2010) (1997)
The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. (2010) (1952)
The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. (2010) (1862)
Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor (1990) (1096)
Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist (1990) (1067)
Interleukin-1 receptor antagonist: role in biology. (1998) (1049)
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. (1990) (980)
The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. (2010) (969)
Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis (1995) (869)
Interleukin-1 receptor antagonist. (1993) (816)
IL‐1, IL‐18, and IL‐33 families of cytokines (2008) (808)
The American College of Rheumatology 1990 criteria for the classification of Henoch-Schönlein purpura. (2010) (796)
The balance between IL-1 and IL-1Ra in disease. (2002) (681)
The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. (2010) (621)
Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. (1991) (588)
The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. (2010) (569)
Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. (1990) (564)
Antibodies against citrullinated proteins enhance tissue injury in experimental autoimmune arthritis. (2006) (548)
Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. (1995) (330)
Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. (1997) (327)
Effects of immune complexes on production by human monocytes of interleukin 1 or an interleukin 1 inhibitor. (1985) (321)
IL-1 family nomenclature (2010) (302)
N-α-Benzoyl-N5-(2-Chloro-1-Iminoethyl)-l-Ornithine Amide, a Protein Arginine Deiminase Inhibitor, Reduces the Severity of Murine Collagen-Induced Arthritis (2011) (252)
The American College of Rheumatology 1990 criteria for the classification of vasculitis. Patients and methods. (2010) (250)
Binding of IL-1 alpha, IL-1 beta, and IL-1 receptor antagonist by soluble IL-1 receptors and levels of soluble IL-1 receptors in synovial fluids. (1994) (247)
The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. (2010) (246)
IL-1 receptor antagonist and IL-1 beta production in human monocytes are regulated differently. (1991) (217)
Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. (1994) (216)
The effects of interleukin-10 on interleukin-1 receptor antagonist and interleukin-1 beta production in human monocytes and neutrophils. (1994) (211)
Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline. (1994) (210)
An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties. (1989) (204)
Biological role of interleukin 1 receptor antagonist isoforms (2000) (188)
Studies on antigen-antibody complexes. I. Elimination of soluble complexes from rabbit circulation. (1971) (179)
Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis (2012) (176)
Physiology of cytokine pathways in rheumatoid arthritis. (2001) (167)
Alternative Complement Pathway Activation Is Essential for Inflammation and Joint Destruction in the Passive Transfer Model of Collagen-Induced Arthritis1 (2006) (158)
Interleukin-1 receptor antagonist production by human keratinocytes. (1992) (157)
Association of rheumatoid arthritis treatment response and disease duration with declines in serum levels of IgM rheumatoid factor and anti-cyclic citrullinated peptide antibody. (2004) (147)
Mechanisms of Inhibition of Collagen-Induced Arthritis by Murine IL-18 Binding Protein 1 (2003) (139)
Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. (2001) (132)
The macrophage receptor for IgG: number and affinity of binding sites. (1973) (131)
Interleukin-1 receptor antagonist in normal and psoriatic epidermis. (1992) (126)
Pathogenic Complement Activation in Collagen Antibody- Induced Arthritis in Mice Requires Amplification by the Alternative Pathway1 (2007) (123)
Role of C3a Receptors, C5a Receptors, and Complement Protein C6 Deficiency in Collagen Antibody-Induced Arthritis in Mice (2012) (115)
Physiologic role of interleukin-1 receptor antagonist (2000) (114)
Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils. (1993) (101)
The differential production of three forms of IL-1 receptor antagonist by human neutrophils and monocytes. (1998) (98)
Characterization of a low molecular weight isoform of IL-1 receptor antagonist. (1998) (97)
Induction of tissue transglutaminase in human peripheral blood monocytes (1984) (95)
FATE OF PREFORMED IMMUNE COMPLEXES IN RABBITS AND RHESUS MONKEYS (1971) (94)
Studies on antigen-antibody complexes. II. Quantification of tissue uptake of soluble complexes in normal and complement-depleted rabbits. (1971) (93)
Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated protein kinase and NF-kappaB pathways. (2003) (92)
The innate immune system in rheumatoid arthritis. (2001) (89)
IN VITRO ADHERENCE OF SOLUBLE IMMUNE COMPLEXES TO MACROPHAGES (1972) (88)
Antibodies against cyclic citrullinated peptide are associated with HLA-DR4 in simplex and multiplex polyarticular-onset juvenile rheumatoid arthritis. (2005) (88)
The mode of action of cytokine inhibitors. (2002) (88)
The pathophysiology and treatment of rheumatoid arthritis. (1997) (84)
Mechanisms of effects of complement inhibition in murine collagen-induced arthritis. (2002) (84)
Production of IL-1 receptor antagonist by human in vitro-derived macrophages. Effects of lipopolysaccharide and granulocyte-macrophage colony-stimulating factor. (1991) (80)
Initiation of the alternative pathway of murine complement by immune complexes is dependent on N-glycans in IgG antibodies. (2008) (79)
Interleukin-4 (IL-4) and IL-13 enhance the effect of IL-1beta on production of IL-1 receptor antagonist by human primary hepatocytes and hepatoma HepG2 cells: differential effect on C-reactive protein production. (1999) (76)
IL-1 beta production in cultured human monocytes is regulated at multiple levels. (1989) (76)
Mouse IL-1 receptor antagonist isoforms: complementary DNA cloning and protein expression of intracellular isoform and tissue distribution of secreted and intracellular IL-1 receptor antagonist in vivo. (1997) (73)
Clinical differentiation between giant cell (temporal) arteritis and Takayasu's arteritis. (1996) (73)
Targeted Inhibition of the Complement Alternative Pathway with Complement Receptor 2 and Factor H Attenuates Collagen Antibody-Induced Arthritis in Mice1 (2009) (72)
Production of IL‐1 receptor antagonist by hepatocytes is regulated as an acute‐phase protein in vivo (2001) (72)
Interleukin-1 receptor antagonist: discovery, structure and properties. (1990) (68)
The human interleukin-1 receptor antagonist (IL1RN) gene is located in the chromosome 2q14 region. (1993) (66)
Tumor necrosis factor-α induces interleukin-1α and interleukin-1 receptor antagonist production by cultured human keratinocytes (1993) (65)
Regulation of nuclear antigen expression on the cell surface of human monocytes. (1992) (65)
LPS-induced expression of the human IL-1 receptor antagonist gene is controlled by multiple interacting promoter elements. (1994) (63)
Humoral and cellular immune mechanisms of neutropenia in patients with Felty's syndrome. (1980) (60)
Cytokines in the rheumatic diseases. (2004) (59)
IgG Induction of IL‐1 Receptor Antagonist Production by Human Monocytes (1994) (58)
Do hyperplastoid cell lines "differentiate themselves to death"? (1975) (58)
Neutral protease secretion by human monocytes. Effect of surface-bound immune complexes (1979) (57)
Expression of interleukin-1α, interleukin-1β, and an interleukin-1 receptor antagonist in human retinal pigment epithelial cells (1992) (55)
Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis: a possible role in the resolution of arthritis. (2001) (54)
Generation and characterization of mice transgenic for human IL‐18‐binding protein isoform a (2003) (54)
Intracellular IL-1 receptor antagonist promoter: cell type-specific and inducible regulatory regions. (1997) (53)
Essential Role of Complement Mannose-Binding Lectin-Associated Serine Proteases-1/3 in the Murine Collagen Antibody-Induced Model of Inflammatory Arthritis (2010) (53)
Rheumatoid factor seropositivity is inversely associated with oral contraceptive use in women without rheumatoid arthritis (2006) (52)
Peripheral blood neutrophil production of interleukin-1 receptor antagonist and interleukin-1β (2005) (51)
Absence of induction of IL-1 production in human monocytes by complement fragments. (1989) (49)
Autoimmune neutropenia in systemic lupus erythematosus. (1978) (49)
Intracellular IL-1 Receptor Antagonist Type 1 Inhibits IL-1-Induced Cytokine Production in Keratinocytes through Binding to the Third Component of the COP9 Signalosome1 (2005) (48)
Interleukin 1 receptor antagonist production in human monocytes is induced by IL-1α, IL-3, IL-4 and GM-CSF (1993) (48)
Characterization of immune complexes and immunoglobulin G antibodies reactive with neutrophils in the sera of patients with Felty's syndrome. (1980) (47)
Enhancement of collagen-induced arthritis in mice genetically deficient in extracellular superoxide dismutase. (2004) (45)
Characteristics of bacterial lipopolysaccharide induction of interleukin 1 synthesis and secretion by human monocytes. (1986) (45)
Serum disappearance and catabolism of homologous immunoglobulin fragments in rats. (1975) (44)
Complement activation pathways in murine immune complex‐induced arthritis and in C3a and C5a generation in vitro (2010) (44)
Human IL-1 receptor antagonist promoter. Cell type-specific activity and identification of regulatory regions. (1992) (42)
Molecular composition and sedimentation characteristics of soluble antigen-antibody complexes. (1972) (40)
Peptidomimetic Fluoromethylketone Rescues Mice from Lethal Endotoxic Shock (1999) (40)
IL-1ra ELISA: reduction and alkylation of synovial fluid eliminates interference by IgM rheumatoid factors. (1991) (40)
Neutrophil-binding immunoglobulin G in systemic lupus erythematosus. (1979) (38)
Mice transgenic for intracellular interleukin‐1 receptor antagonist type 1 are protected from collagen‐induced arthritis (2003) (37)
Prevention of Collagen-Induced Arthritis in Mice Transgenic for the Complement Inhibitor Complement Receptor 1-Related Gene/Protein y1 (2003) (37)
Treatment of rheumatoid arthritis with IL-1 inhibitors (2004) (37)
Loss of Fc receptor activity after culture of human monocytes on surface-bound immune complexes. Mediation by cyclic nucleotides (1980) (34)
Essential Role for the Lectin Pathway in Collagen Antibody–Induced Arthritis Revealed through Use of Adenovirus Programming Complement Inhibitor MAp44 Expression (2014) (33)
Determination of soluble immune complex molar composition and antibody association constants by ammonium sulfate precipitation. (1974) (32)
The effect of complement depletion on wound healing. (1974) (32)
Effect of immune complexes on human neutrophil phagocytic function. (1982) (31)
Essential Role of Surface-Bound Complement Factor H in Controlling Immune Complex–Induced Arthritis (2013) (28)
Roles of Adipocytes and Fibroblasts in Activation of the Alternative Pathway of Complement in Inflammatory Arthritis in Mice (2013) (27)
Lipopolysaccharide and Raf-1 kinase regulate secretory interleukin-1 receptor antagonist gene expression by mutually antagonistic mechanisms (1997) (27)
Lipopolysaccharide and interleukin 1 inhibit interferon-gamma-induced Fc receptor expression on human monocytes. (1987) (26)
The effects of differentiating agents on IL-1 beta production in cultured human monocytes. (1990) (26)
Chronic neutropenia: possible association with Sjögren's syndrome. (1981) (26)
Characteristics of chondrocyte responses to a human interleukin 1-like factor. (1985) (26)
Nonsecretory myeloma. Immunofluorescent demonstration of paraprotein within bone marrow plasma cells (1974) (26)
INTERLEUKINS AND ARTHRITIS IL-1 antagonism in inflammatory arthritis (1993) (25)
Cytokines and cellular interactions in inflammatory synovitis. (2001) (25)
Enhanced production of IL-1 receptor antagonist by alveolar macrophages from patients with interstitial lung disease. (1993) (24)
The biological role of naturally-occurring cytokine inhibitors. (1991) (24)
Differential binding of human interleukin‐1 (IL‐1) receptor antagonist to natural and recombinant soluble and cellular IL‐1 type I receptors (1995) (23)
Inhibiting the effects of cytokines in human diseases. (1995) (23)
Mechanisms of mannose-binding lectin-associated serine proteases-1/3 activation of the alternative pathway of complement. (2011) (22)
Interaction of recombinant monocyte-derived interleukin 1 receptor antagonist with rheumatoid synovial cells. (1991) (19)
Cytokine-induced differentiation of cultured nonadherent macrophages. (1992) (19)
Regulation of interleukin 1 production in human monocytes. I. Effects of gamma-interferon and cycloheximide. (1988) (19)
Characteristics of fibrinolytic enzyme release from human monocytes. (1981) (18)
The effect of complement in adherent immune complexes on Fc and C3 receptor expression in human monocytes. (1981) (16)
Expression of interleukin-1 alpha, interleukin-1 beta, and an interleukin-1 receptor antagonist in human retinal pigment epithelial cells. (1992) (16)
Mixed cryoglobulinemia associated with chronic Q-fever. (1991) (15)
Tumor necrosis factor-alpha induces interleukin-1 alpha and interleukin-1 receptor antagonist production by cultured human keratinocytes. (1993) (14)
Monocyte-reactive antibodies in patients with systemic lupus erythematosus. (1977) (13)
Interleukin-1 inhibitors (1987) (12)
CHAPTER 28 – Interleukin-1 receptor antagonist [IL-1F3] (2003) (11)
The human intracellular interleukin 1 receptor antagonist promoter appropriately regulates gene expression in keratinocytes and gastrointestinal epithelial cells in vivo. (1999) (11)
The role of interleukin-1 receptor antagonist in the prevention and treatment of disease (2003) (11)
IL-1 antagonism in inflammatory arthritis. (1993) (11)
Fate of preformed immune complexes in rabbits and rhesus monkeys. (1971) (11)
Anti-dsDNA antibody assay: high specificity and sensitivity with a filtration radioassay in comparison to low specificity with the standard ELISA. (2007) (11)
A unified list of acronyms for the rheumatology literature. (1998) (10)
Composition and biologic properties of soluble IgG-anti-IgG immune complexes: effects of variations in the specificity of rabbit antibodies to different structural components of human IgG. (1979) (9)
Interleukin 1 receptor antagonist production in human monocytes is induced by IL-1 alpha, IL-3, IL-4 and GM-CSF. (1993) (9)
STUDIES ON ANTIGEN-ANTIBODY COMPLEXES (1971) (8)
May 2001: 32 year old female with dural mass encircling cervical spinal cord (2001) (8)
Grobmyer, S. R. et al. Peptidomimetic fluoromethylketone rescues mice from lethal endotoxic shock: Paradoxical increase in products of caspase 1 (ICE). Mol. Med. 5, 585−594 (1999) (7)
A uniform reference system for rheumatology journals. (1997) (6)
The development of anticytokine therapeutics for rheumatic diseases. (2008) (5)
Stimulation of Production of Interleukin-1 and an Interleukin-1 Inhibitor in Human Monocytes (1985) (5)
The Influence of Personality Characteristics And Test Anxiety on Physician Assistant Clinical Knowledge Rating and Assessment Tool (PACKRAT) Performance (2006) (4)
Arthritis & Rheumatism in 1997 (1997) (4)
Characterization of two species of Fc fragments obtained from rat IgG2a by prolonged papain digestion. (1977) (4)
Arthritis & Rheumatism in 2000. (2000) (4)
Commentary Physiologic role of interleukin-1 receptor antagonist (2000) (3)
Treatment with Cl-amidine, a peptidyl arginine deiminase (PAD) inhibitor, significantly reduces collagen-induced arthritis (CIA) (50.6) (2009) (3)
264 – Approach to the Patient with Rheumatic Disease (2012) (3)
Training in Subspecialty Internal Medicine: On the Chessboard of Health Care Reform (1994) (3)
Independent roles for complement C3a and C5a receptors and the membrane attack complex in the pathogenesis of collagen antibody-induced arthritis in mice: Potential therapeutic implications (2011) (2)
Receptor-targeted immunotherapy. (1992) (2)
Erratum: IL-1 family nomenclature (2011) (2)
Mechanisms of gamma interferon and cycloheximide enhancement of interleukin 1 production in cultured human monocytes (1987) (2)
Cytokine inhibition in the treatment of rheumatic and inflammatory diseases (1998) (2)
Isoform of IL-1 Receptor Antagonist Characterization of a Low Molecular Weight (1998) (2)
Signalosome in Keratinocytes through Binding to the 1 Inhibits IL-1-Induced Cytokine Production Intracellular IL-1 Receptor Antagonist Type (2005) (1)
Potential roles for local adipocytes and fibroblasts in activation of the alternative pathway of complement in inflammatory arthritis in mice (2013) (1)
Human Interleukin-1 Stimulation of Collagenase Production in Rabbit Articular Chondrocytes (1985) (1)
Science on trial. Marcia Angell, MD. New York, W. W. Norton, 1996. 256 pp. Indexed. $27.50 (1996) (1)
James carl steigerwald, 1935–1988 (1988) (1)
Essential role of surface-bound complement factor H in controlling immune complex-induced arthritis (2012) (1)
Risk of Aspiration Pneumonia in the Elderly (2017) (1)
Inhibitors of interleukin-1. (1989) (1)
Clinical therapeutics. (1997) (0)
Charley J. Smyth, MD, 1909‐1997 (1998) (0)
Targeted inhibition of the alternative pathway of complement with complement receptor 2-factor H protein attenuates collagen antibody-induced arthritis in mice (2009) (0)
Gene / Protein y Inhibitor Complement Receptor 1-Related Mice Transgenic for the Complement Prevention of Collagen-Induced Arthritis in (2003) (0)
The alternative pathway of complement alone can mediate collagen antibody-induced arthritis in mice and generate high levels of C5a in vitro (2008) (0)
Interleukin-1 inhibitors encoding DNA sequences, containing the vectors and host cells and a method for producing interleukin-1 inhibitors (1990) (0)
Essential role of complement MASP-1/3 in the murine collagen antibody-induced model of inflammatory arthritis 1 (2010) (0)
Transglutaminases are a group of enzymes that catalyze the covalent conju- gation of amines to protein-bound glutamine residues. The products of transglu- taminase activity are proteins covalently cross-linked by ~-(3"-glutaminyl)-lysine isopeptide bonds and proteins containing covalently conjugated (1984) (0)
ArthritisAntibody-Induced Model of Inflammatory Proteases-1/3 in the Murine Collagen Mannose-Binding Lectin-Associated Serine Essential Role of Complement (2010) (0)
Targeting interleukin-1 in rheumatic diseases (2007) (0)
Antibody-Induced Arthritis in Mice Complement Protein C6 Deficiency in Collagen Role of C3a Receptors, C5a Receptors, and (2012) (0)
Neutrophils and Monocytes of IL-1 Receptor Antagonist by Human The Differential Production of Three Forms (1998) (0)
Interleukin-1 Receptor Antagonist Isoforms in Collagen-Induced Arthritis (1999) (0)
The Alternative Pathway is Necessary and Sufficient for Complement Involvement in the Effector Phase of Anti-Collagen Antibody Induced Arthritis (ACAIA) (2007) (0)
Contributors (2012) (0)
Antibody-Induced Arthritis in Mice Receptor 2 and Factor H Attenuates Collagen Alternative Pathway with Complement Targeted Inhibition of the Complement (2009) (0)
A Unified List of Acronyms for the Rheumatology Literature (1999) (0)
1122 THE AMERICAN COLLEGE OF RHEUMATOLOGY 1990 CRITERIA FOR THE CLASSIFICATION OF GIANT CELL ARTERITIS (2010) (0)
Interleukin-1 and its receptor antagonist in inflammatory arthritis (2015) (0)
Arthritis Murine Collagen Antibody-Induced Model of Lectin-Associated Serine Proteases-1 / 3 in the Essential Role of Complement Mannose-Binding (2010) (0)
The relative roles of tumor necrosis factor alpha (TNF-A) and interleukin-1 (IL-1) in the induction of intercellular adhesion molecule-1 (ICAM-1) in human epidermis by ultraviolet radiation (1993) (0)
MiceComplement in Inflammatory Arthritis in Activation of the Alternative Pathway of Roles of Adipocytes and Fibroblasts in (2013) (0)
The lectin pathway of complement activation participates in the passive transfer model of collagen-induced arthritis (2007) (0)
Collagen-Induced Arthritis Destruction in the Passive Transfer Model of Is Essential for Inflammation and Joint Alternative Complement Pathway Activation (2006) (0)
Issue Information (1986) (0)
Collagen-Induced Arthritis Inhibitor , Reduces the Severity of Murine hine Amide , a Protein Arginine Deiminase-Benzoyl-N 5-( 2-Chloro-1-Iminoethyl )-l-Ornit α (2011) (0)
Results Transglutaminase in Freshly Isolated and Cultured Monocytes (2003) (0)
Antibodies to citruiline-modified proteins enhance tissue injury in inflammatory arthritis. (2005) (0)
O9The alternative pathway is both necessary and sufficient for the complement-dependent injury found in the effector phase of collagen antibody induced arthritis (CAIA) (2007) (0)
IN VITRO A D H E R E N C E OF SOLUBLE I M M U N E CO MP LEX ES TO MACROPHAGES* BY WILLIAM P. AREND$ AND MART MANNIK (2003) (0)
Binding Protein Collagen-Induced Arthritis by Murine IL-18 Mechanisms of Inhibition of (2013) (0)
Collagen Antibody-Induced Arthritis in Mice Complement Protein C6 Deficiency in Role of C3a Receptors, C5a Receptors, and (2011) (0)
I-4 : IL-1 and IL-1 Ra in rheumatoid arthritis (2002) (0)
A recombinant DNA method for the production of a receptor antagonist of interleukin 1 (IL-li) (1989) (0)
Arthritis Reduces the Severity of Murine Collagen-Induced Amide , a Protein Arginine Deiminase Inhibitor ,-Benzoyl-N 5-( 2-Chloro-1-Iminoethyl )-l-Ornithine (2011) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With William p. Arend?

William p. Arend is affiliated with the following schools: